---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001909"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:59:36.330205+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics completes preclinical studies of SIL204 in KRAS-driven colorectal, lung, and pancreatic cancers

## Summary
- SIL204 evaluated in GP2D (colorectal), A427 (lung), and Panc-1 (pancreatic) KRAS-mutant cell lines.
- Company expects to announce comprehensive results within the next few days.
- If positive, SIL204 could expand development strategy beyond pancreatic cancer.
- Global treatment markets for these three KRAS-driven cancers estimated at over $30 billion annually.
- KRAS mutations drive ~90% of pancreatic, ~45% of colorectal, and ~35% of non-squamous NSCLC.

## SEC filing metadata
- accession: 0001178913-25-001909
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/0001178913-25-001909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/zk2533232.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001909
- JSON: https://secwatch.observer/filing/0001178913-25-001909.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.